The immune hypothesis of major depressive disorder in the light of cognitive functions
The immunological-inflammatory theory of major depressive disorder originated in the 1980s, yet it has become the focus of mainstream research today. Nevertheless, the results are controversial: postmortem immunohistochemical detection of central neuronal and glial markers has not led to a clear conclusion, the relationship with the therapeutic response is questionable, and the correlation between peripheral and central markers is poor. A possible solution is detecting inflammatory changes in vivo by positron emission tomography (PET) (e.g., TSPO binding). The importance of this method lies in its direct correlation with clinical changes and in the monitoring of the therapeutic response and its neurological correlates. Of particular importance is the link with cognitive symptoms and cognitive-behavioral therapy. In the present paper, we will highlight some critical results on this issue, showing that the presumed variation in microglia is associated with the cognitive symptoms accompanying mood disorders and provides an appropriate tool for the follow-up of clinical responses to cognitive therapy. We will also address the limitations of currently available methods (e.g., PET ligands' binding specificity, spatial resolution problems, and the possibility of monitoring immunological changes in vivo).
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology - 25(2023), 2 vom: 01. Juni, Seite 92-100 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
A major depresszív zavar immunológiai elmélete a kognitív funkciók tükrében |
|---|
| Beteiligte Personen: |
Keri, Szabolcs [VerfasserIn] |
|---|
| Themen: |
Cognitive impairment |
|---|
| Anmerkungen: |
Date Completed 28.07.2023 Date Revised 28.07.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM359947069 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359947069 | ||
| 003 | DE-627 | ||
| 005 | 20231226081947.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||hun c | ||
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359947069 | ||
| 035 | |a (NLM)37494696 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Keri, Szabolcs |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The immune hypothesis of major depressive disorder in the light of cognitive functions |
| 246 | 3 | 3 | |a A major depresszív zavar immunológiai elmélete a kognitív funkciók tükrében |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2023 | ||
| 500 | |a Date Revised 28.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The immunological-inflammatory theory of major depressive disorder originated in the 1980s, yet it has become the focus of mainstream research today. Nevertheless, the results are controversial: postmortem immunohistochemical detection of central neuronal and glial markers has not led to a clear conclusion, the relationship with the therapeutic response is questionable, and the correlation between peripheral and central markers is poor. A possible solution is detecting inflammatory changes in vivo by positron emission tomography (PET) (e.g., TSPO binding). The importance of this method lies in its direct correlation with clinical changes and in the monitoring of the therapeutic response and its neurological correlates. Of particular importance is the link with cognitive symptoms and cognitive-behavioral therapy. In the present paper, we will highlight some critical results on this issue, showing that the presumed variation in microglia is associated with the cognitive symptoms accompanying mood disorders and provides an appropriate tool for the follow-up of clinical responses to cognitive therapy. We will also address the limitations of currently available methods (e.g., PET ligands' binding specificity, spatial resolution problems, and the possibility of monitoring immunological changes in vivo) | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PET | |
| 650 | 4 | |a cognitive impairment | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a major depressive disorder | |
| 650 | 4 | |a microglia | |
| 650 | 7 | |a TSPO protein, human |2 NLM | |
| 650 | 7 | |a Receptors, GABA |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology |d 2004 |g 25(2023), 2 vom: 01. Juni, Seite 92-100 |w (DE-627)NLM148164447 |x 1419-8711 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:2 |g day:01 |g month:06 |g pages:92-100 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 2 |b 01 |c 06 |h 92-100 | ||